Myasthenia Gravis Market: By Type (Ocular Myasthenia Gravis, Congenital Myasthenia Gravis, Generalized Myasthenia Gravis, Transient Myasthenia Gravis and Others), (Diagnosis and Treatment), End User (Hospitals and Clinics, Diagnostic Centers and Academic and Research Organizations) and By Region-Global Forecast Till 2027

Market Scenario

Market Research Future (MRFR) proclaims that the global myasthenia gravis disease market is estimated to garner 7.5% CAGR during the forecast period (2017-2023). The surging cases of neuromuscular disorders are estimated to favor the market growth globally. Myasthenia gravis is referred to as a neuromuscular disorder which results in the skeletal muscles to weaken. The disease generally occurs due to the impairment of communication between the nerve cells and the muscles and causes difficulty in the relaxation and contraction of muscles. The antibodies present in the body destroy the receptor for acetylcholine at the neuromuscular joint which prevents the muscles from contracting and performing its normal function.

Market Potential and Pitfalls

Myasthenia Gravis can occur both in females and males but usually affect the women under 40 years and the aging population from 50 to 70 years. With surging cases of neuromuscular disorders, a growing number of clinical facilities, and raising awareness regarding the treatment line, the global myasthenia gravis disease is considered to receive a boost. The increasing occurrences of autoimmune disorders, rising spending on healthcare, and a strong pipeline in the treatment are some of the factors contributing to the growth of the market. The surging cases of myasthenia gravis can impact the quality of life, which further fosters its growth. With the growth in R&D activities, the myasthenia gravis disease market is likely to experience a thrust. Moreover, the rising adoption of novel therapies coupled with the favorable reimbursement policies especially in the developed economies has promoted its growth worldwide.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/7267

On the contrary, the ignorance symptoms and signs coupled with the high cost of treatment are some of the top barriers vitiating the market growth across the globe. Moreover, the limited availability of FDA approved drugs is estimated to deter the market growth in the long run.

Global Myasthenia Gravis Disease Market: Segmental Analysis

The global myasthenia gravis disease market has been segmented on the basis of treatment, diagnosis, and end-user.

By mode of diagnosis, the global myasthenia gravis disease market has been segmented into blood tests, imaging, edrophonium tests, electrodiagnostic, pulmonary function tests, and others.

By mode of treatment, the global myasthenia gravis disease market has been segmented into surgery, medication, plasmapheresis and intravenous immunoglobulin, autologous Hematopoietic Stem Cell Transplantation (HSCT), and others.

By mode of end-users, the global myasthenia gravis disease market has been segmented into clinics, hospitals, academic research institutes, and others.

Reginal Insights

Geographically, the myasthenia gravis disease market span across regions namely, Europe, America, Asia Pacific, and the Middle East and Africa.

Considering the global scenario, the American region is estimated to command the largest market share. The growth is ascribed to the surging number of drug manufacturers, increased government funding for the treatment, and growing awareness regarding the long-term effects of muscle dystrophy. Major companies in this region are launching FDA approved drugs which have augmented the commercial access to such drugs on a global scale.

The European region is considered to occupy the second spot and is likely to retain its pole position in the long run. The growth can be ascribed to the adoption of the latest therapies, high availability of advanced treatment facilities, and the presence of skilled medical professionals.

The Asia Pacific region is estimated to be the fastest growing region due to the presence of a large geriatric population base especially in economies like China and Japan. The surging awareness regarding the long-term effects of muscular dystrophies has further contributed to the market growth. Moreover, the rising awareness regarding neuromuscular disorders coupled with the vast improvement made in the healthcare sector in economies like China, India, Malaysia, and Indonesia has further influenced the market growth to a large extent.

Industry Updates

April 01, 2019: Ra Pharmaceuticals, Inc. has recently declared that the data from its Phase 2 clinical trial of zilucoplan for treating generalized myasthenia gravis has been selected for an Emerging Science dual oral and poster presentation at the American Academy of Neurology Annual Meeting in Philadelphia, 2019.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/myasthenia-gravis-market-7267

Competitive Dashboard

The prominent players operating in the global myasthenia gravis disease market comprises AbbVie Inc. (U.S.), F. Hoffmann Roche La Ltd. (Switzerland), Biogen Inc. (U.S.), Fresenius Kabi (Germany), Cipla (India), Sun Pharmaceuticals Industries Ltd. (India), Piramal Healthcare (India), Apotex Corporation (Canada), RPG Life Sciences (India), Teva Pharmaceutical Industries Ltd. (Israel), Bristol-Myers Squibb Company (U.S.), Valeant Pharmaceuticals International (U.S.), Novartis Pharmaceuticals Corporation (Switzerland), GlaxoSmithKline plc (UK), and others.

You may also be interested in..

Dental Chair Market Research Report Global Forecast till 2027

Global Organ-on-a-chip Market Research Report Forecast to 2027

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]